Market Closed -
Saudi Arabian S.E.
08:20:01 2024-06-26 EDT
|
5-day change
|
1st Jan Change
|
146
SAR
|
-0.41%
|
|
+4.29%
|
+26.96%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,050
|
10,262
|
-
|
-
|
Enterprise Value (EV)
1 |
7,766
|
9,944
|
9,777
|
9,607
|
P/E ratio
|
27.5
x
|
28
x
|
25.5
x
|
21.5
x
|
Yield
|
0.87%
|
2.14%
|
2.38%
|
2.89%
|
Capitalization / Revenue
|
7.31
x
|
7.78
x
|
6.98
x
|
6.06
x
|
EV / Revenue
|
7.05
x
|
7.54
x
|
6.65
x
|
5.67
x
|
EV / EBITDA
|
22.6
x
|
22.7
x
|
21.3
x
|
17.7
x
|
EV / FCF
|
31
x
|
36.8
x
|
27.1
x
|
21.7
x
|
FCF Yield
|
3.23%
|
2.72%
|
3.69%
|
4.61%
|
Price to Book
|
-
|
6.4
x
|
5.62
x
|
4.99
x
|
Nbr of stocks (in thousands)
|
70,000
|
70,000
|
-
|
-
|
Reference price
2 |
115.0
|
146.6
|
146.6
|
146.6
|
Announcement Date
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
1,101
|
1,319
|
1,470
|
1,694
|
EBITDA
1 |
-
|
344.3
|
439
|
459.9
|
541.5
|
EBIT
1 |
-
|
313.4
|
411
|
440
|
504
|
Operating Margin
|
-
|
28.47%
|
31.16%
|
29.92%
|
29.75%
|
Earnings before Tax (EBT)
1 |
-
|
315.8
|
399
|
451
|
515.5
|
Net income
1 |
171.3
|
292.4
|
366
|
401.6
|
476.7
|
Net margin
|
-
|
26.56%
|
27.75%
|
27.31%
|
28.14%
|
EPS
2 |
2.450
|
4.180
|
5.230
|
5.740
|
6.817
|
Free Cash Flow
1 |
-
|
250.9
|
270
|
361
|
443
|
FCF margin
|
-
|
22.79%
|
20.47%
|
24.55%
|
26.15%
|
FCF Conversion (EBITDA)
|
-
|
72.85%
|
61.5%
|
78.5%
|
81.8%
|
FCF Conversion (Net income)
|
-
|
85.79%
|
73.77%
|
89.88%
|
92.92%
|
Dividend per Share
2 |
-
|
1.000
|
3.140
|
3.495
|
4.240
|
Announcement Date
|
5/4/23
|
3/25/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
-
|
298.4
|
292.6
|
207.9
|
385.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
84.4
|
-
|
-
|
-
|
103
|
Net margin
|
-
|
-
|
-
|
-
|
26.71%
|
EPS
|
1.210
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/2/23
|
8/15/23
|
11/8/23
|
3/25/24
|
5/9/24
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
284
|
318
|
485
|
655
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
251
|
270
|
361
|
443
|
ROE (net income / shareholders' equity)
|
-
|
22.3%
|
23%
|
22.8%
|
24%
|
ROA (Net income/ Total Assets)
|
-
|
19.1%
|
20%
|
20.4%
|
20.8%
|
Assets
1 |
-
|
1,531
|
1,830
|
1,966
|
2,289
|
Book Value Per Share
2 |
-
|
-
|
22.90
|
26.10
|
29.40
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
45.2
|
65
|
45
|
43
|
Capex / Sales
|
-
|
4.1%
|
4.93%
|
3.06%
|
2.54%
|
Announcement Date
|
5/4/23
|
3/25/24
|
-
|
-
|
-
|
Last Close Price
146.6
SAR Average target price
146.6
SAR Spread / Average Target +0.01% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.96% | 2.74B | | +20.78% | 43.29B | | +27.64% | 22.38B | | +18.74% | 15.51B | | +18.68% | 14.52B | | +54.64% | 12.93B | | -0.05% | 6.79B | | -11.39% | 6.56B | | +17.73% | 5.87B | | -8.87% | 5.73B |
Generic Pharmaceuticals
|